Skip to main content

Advertisement

SpringerLink
Log in

Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and Correlation with Molecular Characteristics

  • Neuro-Oncology (LE Abrey, Section Editor)
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Radiogenomics is a provocative new area of research based on decades of previous work examining the association between radiological and histological features. Many generalized associations have been established linking anatomical imaging traits with underlying histopathology, including associations between contrast-enhancing tumor and vascular and tumor cell proliferation, hypointensity on pre-contrast T1-weighted images and necrotic tissue, and associations between hyperintensity on T2-weighted images and edema or nonenhancing tumor. Additionally, tumor location, tumor size, composition, and descriptive features tend to show significant associations with molecular and genomic factors, likely related to the cell of origin and growth characteristics. Additionally, physiologic MRI techniques also show interesting correlations with underlying histology and genomic programs, including associations with gene expression signatures and histological subtypes. Future studies extending beyond simple radiology–histology associations are warranted in order to establish radiogenomic analyses as tools for prospectively identifying patient subtypes that may benefit from specific therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Notes

  1. Note: the previous work utilized the gene expression classification system by Phillips et al. [8•], whereas the work by Gutman et al. employed the classification system by Verhaak et al. [4•].

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 2013;15 Suppl 2: ii1–56.

  2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.

    Article  CAS  PubMed  Google Scholar 

  3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.

    Article  CAS  PubMed  Google Scholar 

  4. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110. Defines prognostically important gene expression subtypes in GBM.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 2010;12:116–21.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350–4.

    Article  CAS  PubMed  Google Scholar 

  7. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003. Study demonstrates significant therapeutic benefit of temozolomide therapy in MGMT promoter methylated GBM.

    Article  CAS  PubMed  Google Scholar 

  8. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157–73. Defines prognostically important gene expression subtypes of GBM.

    Article  CAS  PubMed  Google Scholar 

  9. Pierallini A, Bonamini M, Pantano P, Palmeggiani F, Raguso M, Osti MF, et al. Radiological assessment of necrosis in glioblastoma: variability and prognostic value. Neuroradiology. 1998;40:150–3.

    Article  CAS  PubMed  Google Scholar 

  10. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol. 1996;27:65–73.

    Article  CAS  PubMed  Google Scholar 

  11. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190–8.

    Article  CAS  PubMed  Google Scholar 

  12. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol. 2005;26:2466–74. First study to define radiographic descriptive features for use in radiogenomic analysis. Forms the basis of the VASARI feature set used by TCGA.

    PubMed  Google Scholar 

  13. Ellingson BM, Lai A, Harris RJ, Selfridge JM, Yong WH, Das K, et al. Probabilistic radiographic atlas of glioblastoma phenotypes. AJNR Am J Neuroradiol. 2013;34:533–40. Study correlates tumor location, volumes, and composition with clinical, molecular, genomic, and interventional phenotypes in >500 GBM patients.

    Article  CAS  PubMed  Google Scholar 

  14. Hobbs SK, Shi G, Homer R, Harsh G, Atlas SW, Bednarski MD. Magnetic resonance image-guided proteomics of human glioblastoma multiforme. J Magn Reson Imaging. 2003;18:530–6.

    Article  PubMed  Google Scholar 

  15. Rees JH, Smirniotopoulos JG, Jones RV, Wong K. Glioblastoma multiforme: radiologic-pathologic correlation. Radiographics. 1996;16:1413–38. Quiz 1462–1413. One of the first studies to explicitly define radiographic–pathologic correlations in GBM.

    Article  CAS  PubMed  Google Scholar 

  16. Russell SM, Elliott R, Forshaw D, Golfinos JG, Nelson PK, Kelly PJ. Glioma vascularity correlates with reduced patient survival and increased malignancy. Surg Neurol. 2009;72:242–6. Discussion 246–247.

    Article  PubMed  Google Scholar 

  17. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell. 2009;15:167–70.

    Article  CAS  PubMed  Google Scholar 

  18. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg. 1987;66:865–74.

    Article  CAS  PubMed  Google Scholar 

  19. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29:15–8.

    Article  CAS  PubMed  Google Scholar 

  20. Pope WB, Chen JH, Dong J, Carlson MR, Perlina A, Cloughesy TF, et al. Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology. 2008;249:268–77. One of the first radiogenomic studies in GBM.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Damadian R. Tumor detection by nuclear magnetic resonance. Science. 1971;171:1151–3.

    Article  CAS  PubMed  Google Scholar 

  22. Hoehn-Berlage M, Tolxdorff T, Bockhorst K, Okada Y, Ernestus RI. In vivo NMR T2 relaxation of experimental brain tumors in the cat: a multiparameter tissue characterization. Magn Reson Imaging. 1992;10:935–47.

    Article  CAS  PubMed  Google Scholar 

  23. Oh J, Cha S, Aiken AH, Han ET, Crane JC, Stainsby JA, et al. Quantitative apparent diffusion coefficients and T2 relaxation times in characterizing contrast enhancing brain tumors and regions of peritumoral edema. J Magn Reson Imaging. 2005;21:701–8.

    Article  PubMed  Google Scholar 

  24. Levin VA, Crafts DC, Norman DM, Hoffer PB, Spire JP, Wilson CB. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg. 1977;47:329–35.

    Article  CAS  PubMed  Google Scholar 

  25. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–14.

    Article  CAS  PubMed  Google Scholar 

  26. Macdonald DR, Cascino TL, Schold Jr SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277–80.

    CAS  PubMed  Google Scholar 

  27. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963–72.

    Article  PubMed  Google Scholar 

  28. Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys. 1993;26:239–44.

    Article  CAS  PubMed  Google Scholar 

  29. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med. 2005;353:811–22.

    Article  CAS  PubMed  Google Scholar 

  30. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci. 2001;24:385–428.

    Article  CAS  PubMed  Google Scholar 

  31. Zlatescu MC, TehraniYazdi A, Sasaki H, Megyesi JF, Betensky RA, Louis DN, et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res. 2001;61:6713–5.

    CAS  PubMed  Google Scholar 

  32. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 2000;14:994–1004.

    CAS  PubMed Central  PubMed  Google Scholar 

  33. Poppleton H, Gilbertson RJ. Stem cells of ependymoma. Br J Cancer. 2007;96:6–10.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011;29:4482–90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Ellingson BM, Cloughesy TF, Pope WB, Zaw TM, Phillips H, Lalezari S, et al. Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. Neuroimage. 2012;59:908–16.

    Article  CAS  PubMed  Google Scholar 

  36. Lim DA, Cha S, Mayo MC, Chen MH, Keles E, VandenBerg S, et al. Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol. 2007;9:424–9.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, et al. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol. 2012;33:1349–55.

    Article  CAS  PubMed  Google Scholar 

  38. Diehn M, Nardini C, Wang DS, McGovern S, Jayaraman M, Liang Y, et al. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A. 2008;105:5213–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Naeini KM, Pope WB, Cloughesy TF, Harris RJ, Lai A, Eskin A, et al. Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. Neuro Oncol. 2013;15:626–34. Study demonstrates how simple volumes and tumor composition can be used to identify the mesenchymal gene expression subtype of GBM.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Zinn PO, Mahajan B, Sathyan P, Singh SK, Majumder S, Jolesz FA, et al. Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS One. 2011;6:e25451. One of the first studies to identify novel genomic signatures solely on the basis of predefined radiographic phenotypes.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Zinn PO, Sathyan P, Mahajan B, Bruyere J, Hegi M, Majumder S, et al. A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature. PLoS One. 2012;7:e41522.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Gutman DA, Cooper LA, Hwang SN, Holder CA, Gao J, Aurora TD, et al. MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology. 2013;267:560–9.

    Article  PubMed Central  PubMed  Google Scholar 

  43. Kuo MD, Gollub J, Sirlin CB, Ooi C, Chen X. Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18:821–31.

    Article  PubMed  Google Scholar 

  44. Rutman AM, Kuo MD. Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol. 2009;70:232–41.

    Article  PubMed  Google Scholar 

  45. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol. 2005;15:297–310.

    Article  CAS  PubMed  Google Scholar 

  46. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8:610–22.

    Article  CAS  PubMed  Google Scholar 

  47. Rome C, Arsaut J, Taris C, Couillaud F, Loiseau H. MMP-7 (matrilysin) expression in human brain tumors. Mol Carcinog. 2007;46:446–52.

    Article  CAS  PubMed  Google Scholar 

  48. Leo C, Giaccia AJ, Denko NC. The hypoxic tumor microenvironment and gene expression. Semin Radiat Oncol. 2004;14:207–14.

    Article  PubMed  Google Scholar 

  49. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell. 2002;13:1977–2000.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Channin DS, Mongkolwat P, Kleper V, Rubin DL. The annotation and image mark-up project. Radiology. 2009;253:590–2.

    Article  PubMed  Google Scholar 

  51. Channin DS, Mongkolwat P, Kleper V, Sepukar K, Rubin DL. The caBIG annotation and image Markup project. J Digit Imaging. 2010;23:217–25.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Colen RR, Vangel M, Wang J, Gutman DA, Hwang SN, Wintermark M, et al. Imaging genomic mapping of an invasive MRI phenotype predicts patient outcome and metabolic dysfunction: a TCGA glioma phenotype research group project. BMC Med Genomics. 2014;7:30.

    Article  PubMed Central  PubMed  Google Scholar 

  53. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  54. Dang CV. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med. 2013;3.

  55. Kaadige MR, Elgort MG, Ayer DE. Coordination of glucose and glutamine utilization by an expanded Myc network. Transcription. 2010;1:36–40.

    Article  PubMed Central  PubMed  Google Scholar 

  56. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol. 2008;26:101–6.

    Article  CAS  PubMed  Google Scholar 

  57. Dang CV. MYC on the path to cancer. Cell. 2012;149:22–35.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  58. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000;92:2029–36.

    Article  CAS  PubMed  Google Scholar 

  59. Bode MK, Ruohonen J, Nieminen MT, Pyhtinen J. Potential of diffusion imaging in brain tumors: a review. Acta Radiol. 2006;47:585–94.

    Article  CAS  PubMed  Google Scholar 

  60. Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS, et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging. 2010;31:538–48.

    Article  PubMed Central  PubMed  Google Scholar 

  61. Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging. 1999;9:53–60.

    Article  CAS  PubMed  Google Scholar 

  62. Lyng H, Haraldseth O, Rofstad EK. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med. 2000;43:828–36.

    Article  CAS  PubMed  Google Scholar 

  63. Guo AC, Cummings TJ, Dash RC, Provenzale JM. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology. 2002;224:177–83.

    Article  PubMed  Google Scholar 

  64. Hayashida Y, Hirai T, Morishita S, Kitajima M, Murakami R, Korogi Y, et al. Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR Am J Neuroradiol. 2006;27:1419–25.

    CAS  PubMed  Google Scholar 

  65. Kinoshita M, Hashimoto N, Goto T, Kagawa N, Kishima H, Izumoto S, et al. Fractional anisotropy and tumor cell density of the tumor core show positive correlation in diffusion tensor magnetic resonance imaging of malignant brain tumors. Neuroimage. 2008;43:29–35.

    Article  CAS  PubMed  Google Scholar 

  66. Kidwell CS, Alger JR, Di Salle F, Starkman S, Villablanca P, Bentson J, et al. Diffusion MRI in patients with transient ischemic attacks. Stroke. 1999;30:1174–80.

    Article  CAS  PubMed  Google Scholar 

  67. Pierpaoli C, Alger JR, Righini A, Mattiello J, Dickerson R, Des Pres D, et al. High temporal resolution diffusion MRI of global cerebral ischemia and reperfusion. J Cereb Blood Flow Metab. 1996;16:892–905.

    Article  CAS  PubMed  Google Scholar 

  68. Verheul HB, Balazs R, van der Sprenkel JW B, Tulleken CA, Nicolay K, Tamminga KS, et al. Comparison of diffusion-weighted MRI with changes in cell volume in a rat model of brain injury. NMR Biomed. 1994;7:96–100.

    Article  CAS  PubMed  Google Scholar 

  69. Wintersperger BJ, Runge VM, Biswas J, Reiser MF, Schoenberg SO. Brain tumor enhancement in MR imaging at 3 Tesla: comparison of SNR and CNR gain using TSE and GRE techniques. Invest Radiol. 2007;42:558–63.

    Article  PubMed  Google Scholar 

  70. Chang SC, Lai PH, Chen WL, Weng HH, Ho JT, Wang JS, et al. Diffusion-weighted MRI features of brain abscess and cystic or necrotic brain tumors: comparison with conventional MRI. Clin Imaging. 2002;26:227–36.

    Article  PubMed  Google Scholar 

  71. Farrell CJ, Hoh BL, Pisculli ML, Henson JW, FG 2nd B, Curry Jr WT. Limitations of diffusion-weighted imaging in the diagnosis of postoperative infections. Neurosurgery. 2008;62:577–83. Discussion 577–583.

    Article  PubMed  Google Scholar 

  72. Kastrup O, Wanke I, Maschke M. Neuroimaging of infections. NeuroRx. 2005;2:324–32.

    Article  PubMed Central  PubMed  Google Scholar 

  73. Barajas Jr RF, Phillips JJ, Parvataneni R, Molinaro A, Essock-Burns E, Bourne G, et al. Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro Oncol. 2012;14:942–54. One of the first studies to use image-guided biopsies to examine the association between physiologic imaging features and histopathology.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  74. Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B. 1996;111:209–19.

    Article  CAS  PubMed  Google Scholar 

  75. Basser PJ. New histological and physiological stains derived from diffusion-tensor MR images. Ann N Y Acad Sci. 1997;820:123–38.

    Article  CAS  PubMed  Google Scholar 

  76. Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252:182–9.

    Article  PubMed  Google Scholar 

  77. Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol. 2012;108:491–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  78. Pope WB, Lai A, Mehta R, Kim HJ, Qiao J, Young JR, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol. 2011;32:882–9.

    Article  CAS  PubMed  Google Scholar 

  79. Phillips H, Sandmann T, Li C, Cloughesy TF, Chinot OL, Wick W, et al. Correlation of molecular subtypes with survival in AVAglio (bevacizumab and radiotherapy and temozolomide for newly diagnosed glioblastoma). J Clin Oncol 2014;32: suppl; abstr 2001.

  80. Pope WB, Mirsadraei L, Lai A, Eskin A, Qiao J, Kim HJ, et al. Differential gene expression in glioblastoma defined by ADC histogram analysis: relationship to extracellular matrix molecules and survival. AJNR Am J Neuroradiol. 2012;33:1059–64. One of the first studies to explore differences in gene expression on the basis of diffusion MR phenotypes.

    Article  CAS  PubMed  Google Scholar 

  81. Drabycz S, Roldan G, de Robles P, Adler D, McIntyre JB, Magliocco AM, et al. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage. 2010;49:1398–405.

    Article  CAS  PubMed  Google Scholar 

  82. Meier P, Zierler KL. On the theory of the indicator-dilution method for measurement of blood flow and volume. J Appl Physiol. 1954;6:731–44.

    CAS  PubMed  Google Scholar 

  83. Stewart GN. Researches on the circulation time and on the influences which affect it. J Physiol. 1897;22:159–83.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  84. Rosen BR, Belliveau JW, Vevea JM, Brady TJ. Perfusion imaging with NMR contrast agents. Magn Reson Med. 1990;14:249–65.

    Article  CAS  PubMed  Google Scholar 

  85. Villringer A, Rosen BR, Belliveau JW, Ackerman JL, Lauffer RB, Buxton RB, et al. Dynamic imaging with lanthanide chelates in normal brain: contrast due to magnetic susceptibility effects. Magn Reson Med. 1988;6:164–74.

    Article  CAS  PubMed  Google Scholar 

  86. Rosen BR, Belliveau JW, Buchbinder BR, McKinstry RC, Porkka LM, Kennedy DN, et al. Contrast agents and cerebral hemodynamics. Magn Reson Med. 1991;19:285–92.

    Article  CAS  PubMed  Google Scholar 

  87. Belliveau JW, Kennedy Jr DN, McKinstry RC, Buchbinder BR, Weisskoff RM, Cohen MS, et al. Functional mapping of the human visual cortex by magnetic resonance imaging. Science. 1991;254:716–9.

    Article  CAS  PubMed  Google Scholar 

  88. Kwong KK, Belliveau JW, Chesler DA, Goldberg IE, Weisskoff RM, Poncelet BP, et al. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc Natl Acad Sci U S A. 1992;89:5675–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  89. Edelman RR, Mattle HP, Atkinson DJ, Hill T, Finn JP, Mayman C, et al. Cerebral blood flow: assessment with dynamic contrast-enhanced T2*-weighted MR imaging at 1.5 T. Radiology. 1990;176:211–20.

    Article  CAS  PubMed  Google Scholar 

  90. Hacklander T, Reichenbach JR, Hofer M, Modder U. Measurement of cerebral blood volume via the relaxing effect of low-dose gadopentetate dimeglumine during bolus transit. AJNR Am J Neuroradiol. 1996;17:821–30.

    CAS  PubMed  Google Scholar 

  91. Cha S, Johnson G, Wadghiri YZ, Jin O, Babb J, Zagzag D, et al. Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med. 2003;49:848–55.

    Article  PubMed  Google Scholar 

  92. Pathak AP, Schmainda KM, Ward BD, Linderman JR, Rebro KJ, Greene AS. MR-derived cerebral blood volume maps: issues regarding histological validation and assessment of tumor angiogenesis. Magn Reson Med. 2001;46:735–47.

    Article  CAS  PubMed  Google Scholar 

  93. Badruddoja MA, Krouwer HG, Rand SD, Rebro KJ, Pathak AP, Schmainda KM. Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps. Neuro Oncol. 2003;5:235–43.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  94. Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med. 1998;40:793–9.

    Article  CAS  PubMed  Google Scholar 

  95. Lev MH, Ozsunar Y, Henson JW, Rasheed AA, Barest GD, Harsh GR, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol. 2004;25:214–21.

    PubMed  Google Scholar 

  96. Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol. 2005;26:266–73.

    PubMed  Google Scholar 

  97. Whitmore RG, Krejza J, Kapoor GS, Huse J, Woo JH, Bloom S, et al. Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg. 2007;107:600–9.

    Article  CAS  PubMed  Google Scholar 

  98. Cooper LA, Gutman DA, Long Q, Johnson BA, Cholleti SR, Kurc T, et al. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One. 2010;5:e12548.

    Article  PubMed Central  PubMed  Google Scholar 

  99. Jain R, Poisson L, Narang J, Gutman D, Scarpace L, Hwang SN, et al. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. Radiology. 2013;267:212–20.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Benjamin M. Ellingson has received the following research support: Roche/Genentech Research Grant, NIH/NCI R21CA167354, UCLA Jonsson Comprehensive Cancer Center Seed Grant, UCLA Radiology Exploratory Research Grant. University of California Cancer Research Coordinating Committee Grant, ACRIN Young Investigator Initiative Grant, National Brain Tumor Society Research Grant, and Siemens Healthcare Research Grant.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Author information

Authors and Affiliations

  1. UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers (CVIB), David Geffen School of Medicine, University of California—Los Angeles, Los Angeles, CA, USA

    Benjamin M. Ellingson

  2. UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California—Los Angeles, Los Angeles, CA, USA

    Benjamin M. Ellingson

  3. UCLA Brain Research Institute (BRI), David Geffen School of Medicine, University of California—Los Angeles, Los Angeles, CA, USA

    Benjamin M. Ellingson

  4. Department of Radiological Sciences, David Geffen School of Medicine, University of California—Los Angeles, 924 Westwood Blvd, Suite 615, Los Angeles, CA, 90024, USA

    Benjamin M. Ellingson

  5. Department of Biomedical Physics, David Geffen School of Medicine, University of California—Los Angeles, Los Angeles, CA, USA

    Benjamin M. Ellingson

  6. Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California—Los Angeles, Los Angeles, CA, USA

    Benjamin M. Ellingson

Authors
  1. Benjamin M. Ellingson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin M. Ellingson.

Additional information

This article is part of the Topical Collection on Neuro-Oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ellingson, B.M. Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and Correlation with Molecular Characteristics. Curr Neurol Neurosci Rep 15, 506 (2015). https://doi.org/10.1007/s11910-014-0506-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11910-014-0506-0

Keywords

Search

Navigation